Paris, 18 November 2021 — EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition (Horizon Europe). This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry.
“We are delighted to be the winner of this highly selective European EIC Accelerator program, and we thank all the stakeholders involved in the European Union Horizon Europe program. This funding illustrates EverZom’s disruptive innovation in the biomanufacturing of extracellular vesicles which will provide new therapeutic modalities for tomorrow’s regenerative medicine, particularly in cardiac, hepatic, and renal indications. We have just reached a key milestone which gives us good financial visibility until the end of 2022 and we expect to raise a further €3M at the end of 2022. Our ambition remains unchanged: to become the European leader in the biomanufacturing of extracellular vesicles,” explains Jeanne Volatron, Co-founder and President of EVerZom.
As a reminder, extracellular vesicles have the capacity to target organs or regenerate tissues in several pathologies such as osteoarthritis, to regrow tissues after a myocardial infarction or even liver and kidney diseases.
Unlocking the challenge to manufacture extracellular vesicles at large scale
EverZom offers a novel production process that is scalable, reproducible and has a robust quality control system. EVerZom’s proprietary innovation consists in applying mechanical stimulation on the cells to trigger massive extracellular vesicles release in a reproducible, standardized manner and at large-scale. This approach allows the production of 10 times more extracellular vesicles in 10 times less time and is directly implemented in systems compatible with clinical certifications to meet high unmet medical needs.
EverZom is already marketing its biomanufacturing services to various European and US biotechs, notably for vesicular treatments of digestive fistula in patients suffering from autoimmune diseases such as Crohn’s disease or in patients who have undergone bariatric surgery. The company plan also to establish co-development programs for drug candidates with other pharmaceutical partners and internal proprietary programs in the future.
The European Innovation Council (EIC) Accelerator is a highly selective competition and aims to support start-ups and SMEs to develop their breakthrough innovations and reinforce European technological sovereignty is strategical sectors such as biotech, artificial intelligence, quantum physics or heavy industry. In 2021, the EIC has awarded grants to 65 start-ups, from 16 different countries, including 12 French start-ups that will receive funding of 2 to 10 million euros.
About EVerZom
EVerZom, a biopharmaceutical company specialized in the biomanufacturing of exosomes, is at the service of regenerative medicine with new biological tools: extracellular vesicles or exosomes, which are today considered as a safer and more practical alternative to cell-based therapies.
Spin-off from the Matières et Systèmes Complexes (MSC) laboratory of the University of Paris and the Centre National de la Recherche Scientifique (CNRS), EVerZom is developing a proprietary industrial process that can be scaled up to produce these extracellular vesicles at high yield. EVerZom’s ambition is to position itself as the leading European biomanufacturer of extracellular vesicles for industrial players developing the vesicular therapies of tomorrow.
EVerZom was co-founded in September 2019 by six co-founder, Jeanne Volatron, CEO, Nicolas Rousseau, COO and the four researchers behind the technology and part of the companý scientific board. For more information: http://everzom.com